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Background: Chemokines, including chemokine (C-X-C motif) ligand 1 (CXCL1), may regulate tumor epithelial-
stromal interactions that facilitate tumor growth and invasion. Studies have linked CXCL1 expression to gastric,
colon and skin cancers, but limited studies to date have described CXCL1 protein expression in human bladder
cancer (BCa).
Methods: CXCL1 protein expression was examined in 152 bladder tissue specimens (142 BCa) by
immunohistochemical staining. The expression of CXCL1 was scored by assigning a combined score based on the
proportion of cells staining and intensity of staining. CXCL1 expression patterns were correlated with
clinicopathological features and follow-up data.
Results: CXCL1 protein expression was present in cancerous tissues, but was entirely absent in benign tissue.
CXCL1 combined immunostaining score was significantly higher in high-grade tumors relative to low-grade tumors
(p = 0.012). Similarly, CXCL1 combined immunostaining score was higher in high stage tumors (T2-T4) than in low
stage tumors (Ta-T1) (p < 0.0001). An increase in the combined immunostaining score of CXCL1 was also associated
with reduced disease-specific survival.
Conclusion: To date, this is the largest study describing increased CXCL1 protein expression in more aggressive
phenotypes in human BCa. Further studies are warranted to define the role CXCL1 plays in bladder carcinogenesis
and progression.
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Chemokines are known to be critical mediators of the
inflammatory response by regulating the recruitment of
immune cells from both the innate and adaptive immune
systems to diseased tissues. Dysregulated expression and
activity of certain chemokines has been implicated in the
initiation and progression of several cancers. Specifically,
the chronic exposure of cells to a chemokine-rich milieu
is associated with macrophage and T cell accumulation,
chronic activation of macrophages, abnormal angiogen-
esis, and DNA damage due to the presence of reactive* Correspondence: deacdoc@aol.com
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reproduction in any medium, provided the oroxygen species [1,2]. Furthermore, chemokines have been
known to regulate multiple processes associated with
tumor progression including primary tumor growth,
tumor angiogenesis and development of metastatic dis-
ease, thus some reports have linked chemokines to more
aggressive cancers [3,4]. One chemokine of interest is
chemokine (C-X-C) ligand 1 (CXCL1), also known as
growth-regulated oncogene-alpha or melanoma growth
stimulatory activity, alpha. CXCL1 has been reported to
be overexpressed in colon, skin and breast cancers [5-8],
but only one study to date has reported on the expression
pattern of CXCL1 protein in human bladder tumors.
Herein, we report the largest study assessing CXCL1 ex-
pression patterns in human bladder cancer (BCa) tissues.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and clinicopathologic
characteristics of 152 subjects comprising IHC study
cohort
IHC cohort
BCa (%) n = 142 Controls (%) n = 10
Median age (range, y) 73 (30–94) 29 (15–48)
Median age (range, y) 73 (30–94) 29 (15–48)
Race
Caucasian 134 (94%) N/A
African American 5 (4%) N/A
Other 3 (2%) N/A




















Figure 1 Expression of CXCL1 protein in human bladder. Representativ
adjacent normal urothelia within section with cancer C. All images were ca
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Under MD Anderson Cancer Center Orlando/Orlando
Health Institutional Review Board approval with waiver
of informed consent, 142 bladder tumor paraffin blocks
and 10 benign bladder paraffin blocks dating from
2002–2009 were identified in the Department of Path-
ology archives at Orlando Health, Inc. The clinicopatho-
logic variables of the study cohort are shown in Table 1.
All paraffin blocks were examined by H&E for histo-
logical verification of disease status.
Immunohistochemistry staining
Paraffin blocks were cut (5 μm sections) and placed on a
Superfrost Plus Microslide. Sections were deparaffinized
followed by antigen retrieval using citric acid buffer
(pH 6.0, 95°C for 20 minutes). Slides were treated with 1%
hydrogen peroxide in methanol to block endogenous per-
oxidase activity. After 20 minutes of blocking in 1% bovine
serum albumin (BSA), the slides were incubated overnight
at 4°C with anti-human CXCL1 antibody (sc-1374; goat
polyclonal, dilution 1/250 in 1% BSA) from Santa Cruz
Biotechnology (Santa Cruz, CA). Next, the slides were in-
cubated with 2 μg/mL of biotinylated anti-goat IgG sec-
ondary antibody (Vector Laboratories, Burlingame, CA)
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Figure 2 Expression of CXCL1 protein in high-grade and high stage human bladder cancer. A, Representative staining of low-grade
bladder tumor and high-grade bladder tumor. Bar graph illustrates combined immunostaining score for CXCL1 expression according to tumor
grade. B, Representative staining of non-muscle invasive bladder cancer (pT1) and muscle invasive bladder cancer (pT3). Bar graph illustrates
combined immunostaining score for CXCL1 expression according to tumor stage. All images were captured at 400× magnification. *, p < 0.01 and
***, p < 0.0001.
A B
Figure 3 Probability of bladder cancer specific survival according to CXCL1 staining patterns. ‘High’ combined immunostaing score for
CXCL1 was associated with a significant reduction in (A) disease-specific survival and (B) overall survival (Log-rank test).
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Table 2 Univariate analysis of disease specific survival and overall survival
Variables Disease-specific survival Overall survival
N HR 95% CI p HR 95% CI p
Age (yrs)
≤ 65 35 1 1
> 65 107 1.88 0.69–5.08 0.21 2.03 0.78–5.25 0.15
Sex
Male 115 1 1
Female 27 1.45 0.47–4.46 0.52 1.3 0.44–3.86 0.63
Tumor grade
Low 11 1 1
High 131 2.97 0.42–20.90 0.27 2.99 0.46–19.58 0.25
Stage
NMIBC 82 1 1
MIBC 60 11.78 4.71–29.43 <0.0001 8.83 3.65–21.32 0.0015
Combined immunostaining score for CXCL1
None / Low 34 1 1
Moderate 53 3.45 0.84–14.13 0.085 2.68 0.76–9.50 0.13
High 55 5.73 1.92–17.10 0.0018 4.63 1.60–13.37 0.0047
Abbreviations: HR Hazard ratio, 95% CI 95% confidence interval, NMIBC Non-muscle invasive bladder cancer, MIBC Muscle invasive bladder cancer.
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Peroxidase Staining kit (Pierce/Thermo Fisher Scientific,
San Jose, CA) and 3, 3′- diaminobenzidine (DAB; Vector
Laboratories), counterstained by hematoxyline, dehydrated,
and mounted with a cover slide. Mouse xenograft tumors
from the human prostate cancer cell line PC-3, known
to stain strongly for CXCL1 [9] were used as a positive
control.
Quantification of CXCL1 expression of bladder cancer
Using light microscopy, two investigators (MM and AL),
who were blinded to patients’ data, interpreted immuno-
staining results. The sections were analyzed and staining
assessed using a semiquantitative grading system based







Combined immunostaining score for CXCL1
None / Low 34
Moderate 53
High 55
HR Hazard ratio, 95% CI 95% confidence interval, NMIBC Non-muscle invasive bladdlocation of immunoreactivity (e.g., nuclear, cytoplasm,
cell membrane, and stroma) was noted. The expression
level of CXCL1 was scored by assigning a proportion
score and an intensity score. The proportion of CXCL1-
positive cells was scored in four grades and represented
the estimated proportion of immunoractive cells (0 = 0%
of cells; 1 = 1% to 40%; 2 = 41% to 75% and 3 = 76% to
100%). The intensity was scored and represented the
average intensity of positive cells (0 = none; 1 = weak; 2
= intermediate and 3 = strong). The proportion and in-
tensity scores were added to obtain a combined immu-
nostaining score for the expression of CXCL1, which
ranged from 0 to 6 (0, none; 1–2, low; 3–4, moderate;
and 5–6, high). A third investigator (CJR) reviewed dis-
crepancies and rendered a final score.overall survival
e-specific survival Overall survival
HR 95% CI p HR 95% CI p
1 1
13.61 2.79–66.39 0.001 7.63 2.25–25.92 0.001
1 1
1.57 0.17–14.58 0.69 1.17 0.21–6.36 0.86
3.05 0.34–27.16 0.32 2.08 0.39–10.98 0.39
er cancer, MIBC Muscle invasive bladder cancer.
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Correlation between the pathologic variables and CXCL1
levels was analyzed using Chi-square test. Disease-specific
survival (DSS) and overall survival (OS) curves were
obtained using the Kaplan-Meier method, and compared
by the log-rank test for each prognostic variable. Variables
with effect on survival in univariate analysis were included
in the Cox proportional hazard regression model. Multi-
variate analysis was performed to identify independent
prognostic variables using a stepwise Cox proportional
hazards regression model. IBM SPSS Version 21 (SPSS
Inc., Chicago, IL) and PRISM software version 5.00 (San
Diego, CA) were utilized for statistical analyses and
plotting the data, respectively. Statistical significance in
this study was set at p < 0.05 and all reported p values
were 2-sided.
Results
We set out to analyze CXCL1 protein levels in benign
and cancerous bladder tissue samples using immunohis-
tochemical staining. In benign bladder tissues, CXCL1
expression was entirely absent (Figure 1A). Conversely,
in tumor tissue, varying CXCL1 expression was found
in both epithelial and stromal components of the tissue
(Figure 1B). Within the stroma, CXCL1 immunoreactiv-
ity was diffuse and was not associated with any specific
cell types. Within the epithelia, CXCL1 immunoreactiv-
ity was localized to the cytoplasm. In many cases we
were able to compare cancerous epithelia cells and
tumor-adjacent, histologically benign epithelial cellsFigure 4 CXCL1 mRNA expression in human bladder cancer from pub
transcriptome profiles of bladder tumor tissues were obtained and analyze
levels for CXCL1 in muscle invasive bladder cancer cases was significantly e
(Sanchez-Carbayo et al., p = 1.72-6 [28], Dyrskjot et al. p = 3.77-6 [29], and Leewithin the same tissue section. Interestingly, tumor-
adjacent urothelia also expressed high levels of CXCL1
(Figure 1C), suggesting that in urothelial components,
early molecular changes occur well before morpho-
logical changes become evident. This finding supports
the ‘field-effect’ phenomenon that has been used to de-
scribe a change in the entire urothelium once a carcin-
oma lesion is established [11].
Based on the combined immunostaining score, CXCL1
protein expression was significantly different between
low-grade and high-grade tumors (p = 0.01). Some 7% of
low-grade tumors exhibited ‘high’ staining, whereas 46%
of high-grade tumors had ‘high’ staining (Figure 2A).
Similarly, higher stage tumors (e.g., MIBC stages T2-T4)
had significantly higher CXCL1 expression (p < 0.0001)
than lower stage counterparts (e.g., NMIBC stages
Ta-T1). For example, 63% of T2-T4 tumors had ‘high’
CXCL1 staining, compared to only 18% of Ta-T1 tu-
mors (Figure 2B).
Due to reduce numbers of cancer samples with ‘none’
or ‘low’ combined immunostaining score, these two
groups were combined for subsequent survival analysis.
Univariate Cox analysis revealed that increased CXCL1
expression represents a poor prognostic factor regarding
DSS (Figure 3A) and OS (Figure 3B) (p = 0.0013 and p =
0.0042, respectively). Reduced DSS and OS were also as-
sociated with MIBC (p < 0.0001 and p = 0.0015, respect-
ively) (Table 2). MIBC was also an independent risk
factor for DSS and OS (p = 0.001 and p = 0.001, respect-
ively) in multivariate analyses (Table 3).lically available datasets. Three public datasets containing
d for CXCL1 expression using Oncomine 3.0. Mean relative mRNA
levated compared to non-muscle invasive bladder cancer cases
et al., p = 1.12-4 [30]).
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With an estimated 70,980 newly diagnosed cases of BCa
and 14,330 deaths in 2012, cancer of the urinary bladder
is the second most common genitourinary malignancy
in the U.S. and among the five most common malignan-
cies worldwide [12]. Urothelial carcinoma, the most
prevalent histologic subtype, accounts for 90% of all BCa
in the US [13]. More than 70% of newly diagnosed BCa
are NMIBC at first presentation and treatment can be
curative with transurethral resection with or without ad-
juvant intravesical therapy. NMIBC possesses a high re-
currence rate (~70%) but a low progression rate (~15%)
and an excellent 5-year survival rate of 94% [14]. Some
thirty percent of patients are diagnosed with MIBC or
advanced BCa. MIBC cases are usually treated by radical
cystectomy or external beam radiation therapy with con-
comitant chemotherapy. The 5-year survival in these
patients does not exceed 50% [15]. Our understanding
regarding the carcinogenesis and progression of BCa is
still limited. Better insight into the molecular background
of BCa is needed in hopes of improving outcomes. Re-
ports have linked BCa initiation to chronic inflammation
[16,17], and the dysregulated expression and activity of
certain chemokines has been implicated in the potential
progression from an inflammatory environment to cancer
initiation [3,4]. This chronic inflammatory milieu is associ-
ated with macrophage and T cell accumulation, chronic
activation of macrophages, abnormal angiogenesis, and
DNA damage due to the presence of reactive oxygen
species [1,2].
CXCL1 has been reported to be overexpressed in gas-
tric, colon, skin and renal cancers [5-8,18]. However, its
presence has also been negatively associated with non-
small cell lung cancers [19], attesting to its complex role
in tumorigenesis and angiogenesis. CXCL1 protein ex-
pression had not previously been intensely investigated
in BCa, but it is functionally closely related to interleukin
8 (IL-8), which has been widely studied in BCa [20-22].
One other study supports the association of CXCL1 in
more aggressive BCa. Based on proteomic profiling of
bladder cancer cell lines, Kawanishi et al. monitored
urinary CXCL1 obtained from 67 patients with BCa [23].
The study showed that urinary CXCL1 levels were
significantly higher in patients with MIBC relative to
NMIBC (p = 0.0028), and that CXCL1 was an independ-
ent factor for predicting the invasive phenotype.
We report the first large-scale study assessing CXCL1
protein expression in human bladder tumor tissues.
Increased expression of CXCL1 was evident in higher
grade and higher stage bladder tumors. Furthermore,
higher CXCL1 levels were associated with a reduction in
disease-specific survival. Similar survival results have
been reported in gastric cancer [24], breast cancer [25]
and melanoma [26,27]. These findings support a role forCXCL1 in bladder tumor initiation and progression, and
further studies are underway to better define the influ-
ence of CXCL1 in BCa. While no previous CXCL1 pro-
tein studies had been reported in bladder tumors, a
number of studies have profiled the BCa transcriptome.
In order to investigate the specific pattern of CXCL1
mRNA expression in bladder tissue we analyzed three
publicly available datasets [28-30] using Oncomine 3.0
[31]. Our data-mining analyses illustrated CXCL1 expres-
sion in BCa tissues, and revealed a significant elevation of
CXCL1 in MIBC compared to NMIBC (Figure 4), further
substantiating our findings that CXCL1 was noted to be
significantly different between NMIBC vs. MIBC. Data re-
lated to tumor grade were not available for analysis.
Our study has several limitations. Though we are able to
demonstrate a significant difference in the protein expres-
sion of CXCL1 in benign tissues compared to cancerous
tissues, our benign cohort was quite small (n = 10). Further-
more, we had a limited range of low-grade tumors (n = 11)
thus hampering detailed statistical analysis of our cohort.
Lastly, follow-up data of our BCa subjects was relatively
short (median follow-up 13 months), which limits long
term prognostication. Additional studies are underway
taking these limitations into consideration.
Conclusions
Our study demonstrated that CXCL1 protein is specific-
ally expressed in human bladder carcinomas and that
increased expression is associated with high-grade and
high stage BCa, and with reduced DSS. Further studies
may provide insight into the molecular mechanisms as-
sociated with a proinflammatory microenvironment that
may contribute to cancer development and progression.
Knowledge of the role of CXCL1 in tumor progression
may facilitate the design of new therapeutic approaches
that inhibit tumor cell growth through selective perturb-
ation of CXCL1 function.
Abbreviations
CXCL1: Chemokine (C-X-C) ligand 1; BCa: Bladder cancer; HR: Hazard rate;
CI: Confidence interval; NMIBC: Non-muscle invasive bladder cancer;
MIBC: Muscle invasive bladder cancer.
Competing interests
The following authors declare that they have no competing interests. Makito
Miyake, Adrienne Lawton, Ge Zhang, Shanti Ross, Jeongsoon Kim, Evan
Gomes Giacoia.
The following authors declare that they have a competing interest. Steve
Goodison – affiliated with Nonagen Bioscience Corp., Virginia Urquidi –
affiliated with Nonagen Bioscience Corp., Charles J Rosser – affiliated with
Nonagen Bioscience Corp.
Authors’ contribution
MM carried out IHC staining, reviewed IHC staining, performed statistical
analysis and drafted M&M section of the manuscript. AL reviewed IHC
staining. GZ, JK and EGG carried out IHC staining. SR collected and organized
clinical data. SG participated in study design and helped to draft the
manuscript. VU collected and organize array data present in Figure 4. CJR
conceived the study, and participated in its design and coordination and
Miyake et al. BMC Cancer 2013, 13:322 Page 7 of 7
http://www.biomedcentral.com/1471-2407/13/322helped to draft the manuscript. All authors read and approved the final
manuscript.Acknowledgements
The work was supported by research grant from Florida Department of
Health James and Esther King Team Science Award 10KT-01 (CJR).
Author details
1Cancer Research Institute, Orlando Health, Orlando, FL 32827, USA.
2Department of Pathology, Orlando Health, Orlando, FL 32806, USA.
3Nonagen Bioscience Corporation, Orlando, FL 32827, USA.
Received: 26 April 2013 Accepted: 12 June 2013
Published: 1 July 2013References
1. Moll NM, Cossoy MB, Fisher E, Staugaitis SM, Tucky BH, Rietsch AM, Chang
A, Fox RJ, Trapp BD, Ransohoff RM: Imaging correlates of leukocyte
accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009,
66:44–53.
2. Gillitzer R, Goebeler M: Chemokines in cutaneous wound healing. J Leukoc
Biol 2001, 69:513–521.
3. Hembruff SL, Cheng N: Chemokine signaling in cancer: implications on
the tumor microenvironment and therapeutic targeting. Cancer Ther.
2009, 7:254–267.
4. Hannelien V, Karel G, Jo VD, Sofie S: The role of CXC chemokines in the
transition of chronic inflammation to esophageal and gastric cancer.
Biochim Biophys Acta 1825, 2012:117–129.
5. Verbeke H, Struyf S, Laureys G, Van Damme J: The expression and role of
CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev 2011,
22:345–358.
6. Dhawan P, Richmond A: Role of CXCL1 in tumorigenesis of melanoma.
J Leukoc Biol 2002, 72:9–18.
7. Vazquez-Martin A, Colomer R, Menendez JA: Protein array technology to
detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J
Cancer 2007, 43:1117–1124.
8. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, Bieche I: NF-
kappa B genes have a major role in inflammatory breast cancer.
BMC Cancer 2008, 8:41.
9. Engl T, Relja B, Blumenberg C, Müller I, Ringel EM, Beecken WD, Jonas D,
Blaheta RA: Prostate tumor CXC-chemokine profile correlates with cell
adhesion to endothelium and extracellular matrix. Life Sci 2006,
78:1784–1793.
10. Eck M, Schmausser B, Scheller K, Brändlein S, Müller-Hermelink HK:
Pleiotropic effects of CXC chemokines in gastric carcinoma: differences
in CXCL8 and CXCL1 expression between diffuse and intestinal types of
gastric carcinoma. Clin Exp Immunol 2003, 134:508–515.
11. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S,
Cocco A, Cheng L: Molecular evidence supporting field effect in
urothelial carcinogenesis. Clin Cancer Res 2005, 11:6512–6519.
12. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63:11–30.
13. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet 2009,
374:239–249.
14. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R,
Soloway M, Akaza H, Böhle A: A review of current guidelines and best
practice recommendations for the management of nonmuscle invasive
bladder cancer by the International Bladder Cancer Group. J Urol 2011,
186:2158–2167.
15. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ,
Sherif A, Witjes JA, European Association of Urology (EAU): Treatment of
muscle-invasive and metastatic bladder cancer: update of the EAU
guidelines. Eur Urol 2011, 59:1009–1018.
16. Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X: Profiling of
genetic variations in inflammation pathway genes in relation to bladder
cancer predisposition. Clin Cancer Res 2008, 14:2236–2244.
17. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J,
Dong Q, Wu X: Polymorphisms in inflammation genes and bladder
cancer: from initiation to recurrence, progression, and survival. J Clin
Oncol 2005, 23:5746–5756.18. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, et al: The role of
CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol
2005, 175:5351–5357.
19. Baird AM, Gray SG, O'Byrne KJ: Epigenetics underpinning the regulation of
the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One 2011,
27:6.
20. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman
HB, Dinney CP: Differential expression of progression-related genes in
the evolution of superficial to invasive transitional cell carcinoma of the
bladder. Oncol Rep 2001, 8:9–15.
21. Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, Crippa A,
Moura CM, Adonias SP, Srougi M, Dall'Oglio MF: Increased expression of
MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer.
BMC Urol 2012, 12:18.
22. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney
CP: Interleukin 8 expression regulates tumorigenicity and metastasis in
human bladder cancer. Cancer Res 2000, 60:2290–2299.
23. Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K,
Nishiyama H, Kamoto T, Mikami Y, Tanaka Y, Jung G, Akiyama H, Nobumasa
H, Guilford P, Reeve A, Okuno Y, Tsujimoto G, Nakamura E, Ogawa O:
Secreted CXCL1 is a potential mediator and marker of the tumor
invasion of bladder cancer. Clin Cancer Res 2008, 14:2579–2587.
24. Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH: Overexpression
of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric
cancer. Ann Oncol 2011, 22:2267–2276.
25. Bièche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, Guinebretière
JM, Burlinchon S, Lidereau R, Lazennec G: CXC chemokines located in the
4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 2007,
14:1039–1052.
26. Middleman BR, Friedman M, Lawson DH, DeRose PB, Cohen C: Melanoma
growth stimulatory activity in primary malignant melanoma: prognostic
significance. Mod Pathol 2002, 15:532–537.
27. Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick M,
Nirodi C, Beauchamp D, Johnson KN, Richmond A: Mechanism and
biological significance of constitutive expression of MGSA/GRO
chemokines in malignant melanoma tumor progression. J Leukoc Biol
1997, 62:588–597.
28. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C: Defining
molecular profiles of poor outcome in patients with invasive bladder
cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24:778–789.
29. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S,
Knowles M, Malmström PU, de la Torre M, Wester K, Allory Y, Vordos D,
Caillault A, Radvanyi F, Hein AM, Jensen JL, Jensen KM, Marcussen N,
Orntoft TF: Gene expression signatures predict outcome in non-muscle
-invasive bladder carcinoma: a multicenter validation study. Clin Cancer
Res 2007, 13:3545–3551.
30. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ,
Chu IS: Expression signature of E2F1 and its associated genes predict
superficial to invasive progression of bladder tumors. J Clin Oncol 2010,
28:2660–2667.
31. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette
T, Pandey A, Chinnaiyan AM: ONCOMINE: a cancer microarray database
and integrated data-mining platform. Neoplasia 2004, 6:1–6.
doi:10.1186/1471-2407-13-322
Cite this article as: Miyake et al.: Chemokine (C-X-C) ligand 1 (CXCL1)
protein expression is increased in aggressive bladder cancers. BMC
Cancer 2013 13:322.
